# Biotech Daily Digest — 2025-12-17

**37 items from 4 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 7 items
- Fierce Biotech: 7 items
- arXiv q-bio: 22 items


## Eli Lilly Press Releases

- **[Lilly to participate in J.P. Morgan Healthcare Conference](https://investor.lilly.com/news-releases/news-release-details/lilly-participate-jp-morgan-healthcare-conference-6)**  
  _Tue, 16 Dec 2025 10:00:00 -0500_  
  INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 44 th Annual J.P. Morgan Healthcare Conference , Jan. 12-15, 2025 . David A. Ricks , Lilly chair and CEO, will take part in a fireside chat on Tuesday Jan. 13 at 5:15 p.m., Eastern time .


## Endpoints News

- **[Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney disease](https://endpoints.news/hansas-enzyme-therapy-flunks-phase-3-trial-in-rare-kidney-disease/)**  
  _Wed, 17 Dec 2025 11:20:22 +0000_  
  Hansa Biopharma said Tuesday that its IgG-targeting treatment candidate has failed a late-stage study in a rare type of kidney disease due to an overperforming control arm.

 The Swedish biotech’s imlifidase plus standard of care ...

- **[DBV charts new path to market peanut allergy patch after Phase 3 success](https://endpoints.news/dbv-charts-new-path-to-market-peanut-allergy-patch-after-phase-3-success/)**  
  _Tue, 16 Dec 2025 21:12:26 +0000_  
  DBV Technologies said its peanut allergy patch succeeded in a Phase 3 trial, setting the company up for another FDA submission after a drawn-out saga with regulators.

 The trial enrolled more than 650 children ages ...

- **[Verge Genomics' ALS drug fails as biotech shifts to partner model](https://endpoints.news/verge-genomics-als-drug-fails-as-biotech-shifts-to-partner-model/)**  
  _Tue, 16 Dec 2025 20:04:38 +0000_  
  Verge Genomics' sole clinical-stage drug has failed, and the California biotech will shift to a partnership model for its AI-driven discovery platform, Endpoints News has learned.

 The biotech's VRG50635 did not meet the bar for ...

- **[Mythic Therapeutics shuts down, ends ADC trial as funding dries up](https://endpoints.news/mythic-therapeutics-shuts-down-ends-adc-trial-as-funding-dries-up/)**  
  _Tue, 16 Dec 2025 18:51:01 +0000_  
  Mythic Therapeutics has ended operations, terminating its sole clinical trial after failing to raise enough money to move forward, Endpoints News has learned.

 The Boston-area biotech "pursued various capital solutions during 2025 to fund its ...

- **[Nektar's immunology drug misses in Phase 2b, execs cite enrollment errors](https://endpoints.news/nektars-immunology-drug-misses-in-phase-2b-execs-cite-enrollment-errors/)**  
  _Tue, 16 Dec 2025 16:28:59 +0000_  
  Nektar Therapeutics said a Phase 2b study for its lead immunology drug failed in severe alopecia, but executives blamed the miss on trial enrollment errors and plan to advance the program into pivotal testing.  ...

- **[Pfizer bets big on obesity to offset major patent cliff](https://endpoints.news/pfizer-bets-big-on-obesity-to-offset-major-patent-cliff/)**  
  _Tue, 16 Dec 2025 16:16:07 +0000_  
  Pfizer said it plans to start 15 new studies in obesity next year, many of them in Phase 3, as it seeks to replace about $17 billion in lost revenue by the end of the ...

- **[J&J backs financing round for Stanford CAR-T cell therapy spinout Link Cell](https://endpoints.news/jj-backs-financing-round-for-stanford-car-t-cell-therapy-spinout-link-cell/)**  
  _Tue, 16 Dec 2025 16:03:20 +0000_  
  Link Cell Therapies launched Monday with a $60 million Series A round to fund the creation of the next wave of CAR-T therapies.

 The startup plans to go after the treatment of solid tumors, where ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/harbour-biomed-docks-bristol-myers-squibb-90m-upfront-antibodies-deal" hreflang="en">Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B</a>](https://www.fiercebiotech.com/biotech/harbour-biomed-docks-bristol-myers-squibb-90m-upfront-antibodies-deal)**  
  _Dec 17, 2025 7:57am_  
  Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour BioMed for a multiyear research deal.

- **[<a href="https://www.fiercebiotech.com/biotech/addition-tx-does-math-and-emerges-stealth-100m-biotech-vets-exec-team" hreflang="en">Addition Tx does the math and emerges from stealth with $100M, biotech vets on exec team</a>](https://www.fiercebiotech.com/biotech/addition-tx-does-math-and-emerges-stealth-100m-biotech-vets-exec-team)**  
  _Dec 17, 2025 2:40am_  
  University of California spinout Addition Therapeutics has uncloaked, revealing “breakthrough” PRINT technology it hopes will fuel a new wave of genetic medicine.

- **[<a href="https://www.fiercebiotech.com/biotech/nektar-claims-phase-2-alopecia-success-after-excluding-patients-who-should-never-have-been" hreflang="en">Nektar claims phase 2 alopecia success after excluding patients who 'should never have been enrolled'</a>](https://www.fiercebiotech.com/biotech/nektar-claims-phase-2-alopecia-success-after-excluding-patients-who-should-never-have-been)**  
  _Dec 16, 2025 4:26pm_  
  Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia areata, even after the asset narrowly missed the main goal of a midstage trial.

- **[<a href="https://www.fiercebiotech.com/medtech/siemens-healthineers-taps-alzpath-alzheimers-blood-test-biomarker" hreflang="en">Siemens Healthineers taps ALZpath for Alzheimer's blood test biomarker</a>](https://www.fiercebiotech.com/medtech/siemens-healthineers-taps-alzpath-alzheimers-blood-test-biomarker)**  
  _Dec 16, 2025 1:32pm_  
  ALZpath licensed out its pTau-217 antibody, currently under development, which Siemens Healthineers plans to incorporate in its Atellica immunoassay platforms.

- **[<a href="https://www.fiercebiotech.com/biotech/aldeyra-dry-eye-disease-candidate-hit-fda-delay-after-shifting-agency-guidance-company-says" hreflang="en">Aldeyra dry eye disease candidate hit by FDA delay amid shifting agency guidance, biotech says</a>](https://www.fiercebiotech.com/biotech/aldeyra-dry-eye-disease-candidate-hit-fda-delay-after-shifting-agency-guidance-company-says)**  
  _Dec 16, 2025 11:11am_  
  The FDA has delayed an approval decision for Aldeyra Therapeutics’ lead dry eye disease candidate, adding another detour to the candidate’s winding road to potentially reach the market.

- **[<a href="https://www.fiercebiotech.com/biotech/xoma-acquires-another-struggling-biotech-time-zeroing-generation-bio" hreflang="en">Xoma acquires another struggling biotech, this time zeroing in on Generation Bio</a>](https://www.fiercebiotech.com/biotech/xoma-acquires-another-struggling-biotech-time-zeroing-generation-bio)**  
  _Dec 16, 2025 9:52am_  
  Xoma, which styles itself as a “biotech royalty aggregator,” has struck a deal to acquire Generation Bio for roughly $4.29 per share at the time of the planned merger’s close.

- **[<a href="https://www.fiercebiotech.com/biotech/deal-making-flurry-continues-genentech-offers-caris-11b-biobucks-cancer-collab" hreflang="en">December deal flurry rolls on with Genentech-Caris cancer collab worth up to $1.1B</a>](https://www.fiercebiotech.com/biotech/deal-making-flurry-continues-genentech-offers-caris-11b-biobucks-cancer-collab)**  
  _Dec 16, 2025 10:12am_  
  A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and crafting a multi-year cancer collaboration with Caris Life Sciences.


## arXiv q-bio

- **[Ecological Management of Wild Oat (Avena fatua L.) in Winter Wheat: Modeling Yield Loss and Determination of Economic Thresholds under Varying Crop Densities](https://arxiv.org/abs/2512.13718)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.13718v1 Announce Type: new 
Abstract: Wild oat (Avena fatua L.) is widely recognized as one of the most detrimental grassy weeds in winter wheat production systems globally. While chemical control remains the dominant strategy, the reliance on herbicides without considering Economic Injury Levels (EIL) has…

- **[Graph AI generates neurological hypotheses validated in molecular, organoid, and clinical systems](https://arxiv.org/abs/2512.13724)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.13724v1 Announce Type: new 
Abstract: Neurological diseases are the leading global cause of disability, yet most lack disease-modifying treatments. We present PROTON, a heterogeneous graph transformer that generates testable hypotheses across molecular, organoid, and clinical systems. To evaluate PROTON, we…

- **[An Improved Inverse Method for Estimating Disease Transmission Rates in Low-Prevalence Epidemics](https://arxiv.org/abs/2512.13759)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.13759v1 Announce Type: new 
Abstract: The accurate estimation of time-varying transmission rates is fundamental for understanding infectious disease dynamics and implementing effective public health interventions. To this end, we propose an improved inverse method for estimating time-varying transmission ra…

- **[Neuromodulation-inspired gated associative memory networks:extended memory retrieval and emergent multistability](https://arxiv.org/abs/2512.13859)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.13859v1 Announce Type: new 
Abstract: Classical autoassociative memory models have been central to understanding emergent computations in recurrent neural circuits across diverse biological contexts. However, they typically neglect neuromodulatory agents that are known to strongly shape memory capacity and…

- **[Forecasting Excessive Anesthesia Depth Using EEG {\alpha}-Spindle Dynamics and Machine Learning](https://arxiv.org/abs/2512.14160)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14160v1 Announce Type: new 
Abstract: Objectives. Accurately predicting transitions to anesthetic drugs overdosage is a critical challenge in general anesthesia as it requires the identification of EEG indicators relevant for anticipating the evolution of the depth of anesthesia. Methods. In this study, we…

- **[Spatio-temporal Moran dynamics in continuous media](https://arxiv.org/abs/2512.14171)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14171v1 Announce Type: new 
Abstract: Understanding how natural selection unfolds across space and time is a central problem in evolutionary biology. Classic models such as the Moran process capture stochastic birth-death dynamics in structured populations, while reaction-diffusion equations like the Fisher…

- **[Temporal interference stimulation for deep brain neuromodulation in humans](https://arxiv.org/abs/2512.14359)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14359v1 Announce Type: new 
Abstract: For decades, focal non-invasive neuromodulation of deep brain regions has not been possible because of the steep depth-focality trade-off of conventional non-invasive brain stimulation (NIBS) techniques, such as transcranial magnetic stimulation (TMS) or classical trans…

- **[Absement: Quantitative Assessment of Metabolic Cost during Quasi-Isometric Muscle Loading](https://arxiv.org/abs/2512.13720)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.13720v1 Announce Type: cross 
Abstract: Accurate quantitative assessment of metabolic cost during static posture holding is a strategically important problem in biomechanics and physiology. Traditional metrics such as ``time under tension'' are fundamentally insufficient, because they are scalar quantities…

- **[A Complete Guide to Spherical Equivariant Graph Transformers](https://arxiv.org/abs/2512.13927)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.13927v1 Announce Type: cross 
Abstract: Spherical equivariant graph neural networks (EGNNs) provide a principled framework for learning on three-dimensional molecular and biomolecular systems, where predictions must respect the rotational symmetries inherent in physics. These models extend traditional messa…

- **[Informing Acquisition Functions via Foundation Models for Molecular Discovery](https://arxiv.org/abs/2512.13935)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.13935v1 Announce Type: cross 
Abstract: Bayesian Optimization (BO) is a key methodology for accelerating molecular discovery by estimating the mapping from molecules to their properties while seeking the optimal candidate. Typically, BO iteratively updates a probabilistic surrogate model of this mapping and…

- **[Accelerating MHC-II Epitope Discovery via Multi-Scale Prediction in Antigen Presentation](https://arxiv.org/abs/2512.14011)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14011v1 Announce Type: cross 
Abstract: Antigenic epitope presented by major histocompatibility complex II (MHC-II) proteins plays an essential role in immunotherapy. However, compared to the more widely studied MHC-I in computational immunotherapy, the study of MHC-II antigenic epitope poses significantly…

- **[EXAONE Path 2.5: Pathology Foundation Model with Multi-Omics Alignment](https://arxiv.org/abs/2512.14019)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14019v1 Announce Type: cross 
Abstract: Cancer progression arises from interactions across multiple biological layers, especially beyond morphological and across molecular layers that remain invisible to image-only models. To capture this broader biological landscape, we present EXAONE Path 2.5, a pathology…

- **[When many noisy genes optimize information flow](https://arxiv.org/abs/2512.14055)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14055v1 Announce Type: cross 
Abstract: It often is emphasized that gene expression is noisy. A seemingly contradictory view is that control mechanisms have been optimized to squeeze as much information as possible out of a limited number of molecules. Here we revisit these issues in a simple model where a…

- **[AnySleep: a channel-agnostic deep learning system for high-resolution sleep staging in multi-center cohorts](https://arxiv.org/abs/2512.14461)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14461v1 Announce Type: cross 
Abstract: Sleep is essential for good health throughout our lives, yet studying its dynamics requires manual sleep staging, a labor-intensive step in sleep research and clinical care. Across centers, polysomnography (PSG) recordings are traditionally scored in 30-s epochs for p…

- **[Linguists should learn to love speech-based deep learning models](https://arxiv.org/abs/2512.14506)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2512.14506v1 Announce Type: cross 
Abstract: Futrell and Mahowald present a useful framework bridging technology-oriented deep learning systems and explanation-oriented linguistic theories. Unfortunately, the target article's focus on generative text-based LLMs fundamentally limits fruitful interactions with lin…

- **[Decoding Emotional Trajectories: A Temporal-Semantic Network Approach for Latent Depression Assessment in Social Media](https://arxiv.org/abs/2305.13127)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2305.13127v3 Announce Type: replace 
Abstract: The early identification and intervention of latent depression are of significant societal importance for mental health governance. While current automated detection methods based on social media have shown progress, their decision-making processes often lack a clin…

- **[Arbor-TVB: A Novel Multi-Scale Co-Simulation Framework with a Case Study on Neural-Level Seizure Generation and Whole-Brain Propagation](https://arxiv.org/abs/2505.16861)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2505.16861v2 Announce Type: replace 
Abstract: Computational neuroscience has traditionally focused on isolated scales, limiting understanding of brain function across multiple levels. While microscopic models capture biophysical details of neurons, macroscopic models describe large-scale network dynamics. Integ…

- **[Multi-factor modeling of chlorophyll-a in South China's subtropical reservoirs using long-term monitoring data for quantitative analysis](https://arxiv.org/abs/2507.19553)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2507.19553v2 Announce Type: replace 
Abstract: Eutrophication and harmful algal blooms, driven by complex interactions among nutrients and climate, threaten freshwater ecosystems globally, particularly in densely populated Asian regions.Understanding interactions among water temperature, nutrient levels, and chl…

- **[Property-Isometric Variational Autoencoders for Sequence Modeling and Design](https://arxiv.org/abs/2509.14287)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2509.14287v2 Announce Type: replace 
Abstract: Biological sequence design (DNA, RNA, or peptides) with desired functional properties has applications in discovering novel nanomaterials, biosensors, antimicrobial drugs, and beyond. One common challenge is the ability to optimize complex high-dimensional propertie…

- **[Toric Multivariate Gaussian Models from Symmetries in a Tree](https://arxiv.org/abs/2412.00895)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2412.00895v2 Announce Type: replace-cross 
Abstract: Given a rooted tree $T$ on $n$ non-root leaves with colored and zeroed nodes, we construct a linear space $L_T$ of $n\times n$ symmetric matrices with constraints determined by the combinatorics of the tree. When $L_T$ represents the covariance matrices of a G…

- **[Papanicolaou Stain Unmixing for RGB Image Using Weighted Nucleus Sparsity and Total Variation Regularization](https://arxiv.org/abs/2506.20450)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2506.20450v3 Announce Type: replace-cross 
Abstract: The Papanicolaou stain, consisting of five dyes, provides extensive color information essential for cervical cancer cytological screening. The visual observation of these colors is subjective and difficult to characterize. Direct RGB quantification is unreliab…

- **[Measurement of tissue viscosity to relate force and motion in collective cell migration](https://arxiv.org/abs/2508.11518)**  
  _Wed, 17 Dec 2025 00:00:00 -0500_  
  arXiv:2508.11518v2 Announce Type: replace-cross 
Abstract: In tissue development, wound healing, and cancer invasion, coordinated cell motion arises from active forces produced by the cells. The relationship between force and motion remains unclear, however, because the forces result from a sum of contributions from a…
